Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
Trial ID or NCT#
NCT04092673
Status
RECRUITING
Purpose
This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of Zotatifin (eFT226) in subjects with selected advanced solid tumor malignancies.
Official Title
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects With Selected Advanced Solid Tumor Malignancies
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Lisa Marie Kody
lkody@stanford.edu
View on ClinicalTrials.gov
